CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The EU Member States shall ensure that: 
The Marketing Authorisation Holder (MAH) shall ensure that updated physician information packs 
are provided to all ophthalmology clinics where Lucentis is expected to be used. The physician 
information pack should contain the following: 
 
 
 
 
Physician information 
Intravitreal injection procedure video 
Intravitreal injection procedure pictogram 
Patient information packs 
The physician information should contain the following key elements: 
 
 
 
 
 
 
 
The Summary of Product Characteristics 
Sterile techniques, including periocular and ocular disinfection, to minimise risk of infection  
Use of antibiotics 
Use of povidone iodine or equivalent 
Techniques for the intravitreal injection 
Key signs and symptoms of IVT injection related adverse events 
Management of IVT injection related adverse events 
Patient information leaflet 
How to prepare for Lucentis treatment 
The patient information pack should be provided in the form of both patient information booklets and 
audio-CD that contain following key elements: 
 
 
  What are the steps following treatment with Lucentis 
 
  When to seek urgent attention from the health care provider 
Key signs and symptoms of serious adverse events 
2 
 
 
 
 
 
 
 
